Skip to content
Companies

Zeo ScientifiX

Perinatal-derived biologics for degenerative diseases

Raised to date

$500K

of $5M offered across 1 Form D filing

Still open
$4.5M
Investors
2
Last filed
Dec 5, 2025

About

Zeo ScientifiX, Inc., formerly known as Organicell Regenerative Medicine, Inc., is a publicly traded, clinical-stage biopharmaceutical company. It focuses on researching, developing, and manufacturing biological therapeutics derived from perinatal sources to treat degenerative diseases and support regenerative medicine applications.

The company's primary differentiator is its proprietary perinatal-sourced biologic technology platform, which is supported by ethical sourcing practices and rigorous batch testing protocols to ensure product quality and chain-of-custody ethics.

Funding

  • EquityFiled Dec 5, 2025Form D
    $500K/ $5M

Product

Zofin

Clinical-Stage Therapeutic

Zofin is the company's lead clinical candidate, an acellular biologic therapeutic formulated from perinatal sources. It is currently advancing through Phase I/II clinical trials for its potential to treat conditions such as COVID-19, chronic obstructive pulmonary disease (COPD), and knee osteoarthritis.

  • Acellular biologic therapeutic
  • Derived from perinatal sources
  • Currently in Phase I/II clinical trials

Built for

The company targets healthcare practitioners in specialized medical fields, including regenerative medicine specialists, orthopedic clinics, wound care facilities, and aesthetic medicine practices.

People on file